Doylestown PA, USA and Abingdon, Oxon, UK, 15 September 2020 – Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces the determination of a Class I MHC expression library, or ligandome, for SARS-Cov-2 infected cells, in collaboration with George Mason University (‘GMU’), National Center for Biodefense and Infectious Diseases, Virginia, USA.
{iframe}https://www.streetinsider.com/Globe+Newswire/Emergex+Vaccines+and+George+Mason+University+Identify+T-Cell+Epitopes+Presented+by+SARS-Cov-2+Infected+Cells/17356840.html{/iframe}